EUVIMEDEUVIMED entdecken
Crossref

Evaluation of important human CYP450 isoforms and P‐glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after intensifying treatment regimen using Geneva cocktail

Navid Neyshaburinezhad iD, Nooshin Shirzad, Mohammadreza Rouini, Soha Namazi, Mohammadreza Khoshayand, Alireza Esteghamati, Manouchehr Nakhjavani, Hengameh Ghasim, Yvonne Gloor, Youssef Daali, Yalda H Ardakani

Basic & Clinical Pharmacology & Toxicology · 2023

DOI: 10.1111/bcpt.13840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2023. Verfasst von Navid Neyshaburinezhad und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present study evaluates the influence of type 2 diabetes (T2D) on important CYP450 (CYP) isoforms and P‐glycoprotein (Pgp) transporter activities before and 3 months after an intensifying treatment regimen involving 40 patients. Results have been compared with 21 non‐T2D healthy participants (the control group). CYPs and Pgp activities were assessed after administering the Geneva cocktail. The mean metabolic ratios (MR) for CYP2B6 (1.81 ± 0.93 versus 2.68 ± 0.87), CYP2C19 (0.420 ± 0.360 versus 0.687 ± 0.558) and CYP3A4/5 (0.487 ± 0.226 versus 0.633 ± 0.254) significantly decreased in T2D patients compared to the control group (p < 0.05). CYP2C9 (0.089 ± 0.037 versus 0.069 ± 0.017) activities slightly increased in diabetic patients, and no difference was observed regarding CYP1A2 (0.154 ± 0.085 versus 0.136 ± 0.065), CYP2D6 (1.17 ± 0.56 versus 1.24 ± 0.83), and Pgp activities in comparison to the control group. Three months after the intensifying treatment regimen, MRs of CYP2C9 (0.080 ± 0.030) and CYP3A4/5 (0.592 ± 0.268) improved significantly and were not statistically different compared to the control group (P > 0.05). Several covariables, such as inflammatory markers (IL‐1β and IL‐6), genotypes, diabetes and demographic‐related factors, were considered in the analyses. The results indicate that chronic inflammatory status associated with T2D modulates CYP450 activities in an isoform‐specific manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3ADiabetes Mellitus, Type 2HumansATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemPhenotypeGenotypeProtein IsoformsATP Binding Cassette Transporter, Subfamily B

Stichwörter der Autor:innen

CYP450 phenotype and genotypeinflammationpersonalized medicinephenoconversiontype 2 diabetes

Substanzen

Cytochrome P-450 CYP3AATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemProtein IsoformsATP Binding Cassette Transporter, Subfamily B

Autor:innen und Institutionen

  • Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.

ORCID-Profile: Navid Neyshaburinezhad

Zitieren

APA

Neyshaburinezhad, N., Shirzad, N., Rouini, M., Namazi, S., Khoshayand, M., Esteghamati, A., Nakhjavani, M., Ghasim, H., Gloor, Y., Daali, Y., & Ardakani, Y. H. (2023). Evaluation of important human CYP450 isoforms and P‐glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after intensifying treatment regimen using Geneva cocktail. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13840

Vancouver

Neyshaburinezhad N, Shirzad N, Rouini M, Namazi S, Khoshayand M, Esteghamati A, et al. Evaluation of important human CYP450 isoforms and P‐glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after intensifying treatment regimen using Geneva cocktail. Basic & Clinical Pharmacology & Toxicology. 2023. doi:10.1111/bcpt.13840

BibTeX
@article{Neyshaburinezhad2023,
  author = {Neyshaburinezhad, Navid and Shirzad, Nooshin and Rouini, Mohammadreza and Namazi, Soha and Khoshayand, Mohammadreza and Esteghamati, Alireza and Nakhjavani, Manouchehr and Ghasim, Hengameh and Gloor, Yvonne and Daali, Youssef and Ardakani, Yalda H},
  title = {Evaluation of important human CYP450 isoforms and P‐glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after intensifying treatment regimen using Geneva cocktail},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2023},
  doi = {10.1111/bcpt.13840}
}
Kostenlos starten →